Healthcare providers, suppliers, compliance leaders, and private equity-backed platforms may prepare for increasing operational, ...

In the latest effort by the Trump administration to reduce costs and increase access to anti-obesity medications like Ozempic ...

Starting in July, Medicare beneficiaries may be able to get a GLP-1 prescription for weight loss for $50 a month. It’s a ...

Unchecked MA expansion limits patient choice, access to care as health plans profit ...

Nearly six in 10 retirees anticipated that Medicare would cover a greater share of their healthcare costs, according to a new ...

The U.S. Supreme Court on Monday declined to hear a pharmaceutical industry challenge to the Medicare drug price negotiation ...

Millions of older Americans may have access for the first time to obesity drugs at a low price of $50 a month starting in ...

The U.S. Supreme Court has declined to hear petitions from six major drugmakers challenging the Medicare Drug Price Negotiation Program, leaving in place lower court rulings that upheld the program ...

The BALANCE program was intended to cover weight-loss drugs for Medicaid beneficiaries, but is delayed. A new solution with some downsides takes its place.

Medicare loses up to $100 billion a year to fraud. Learn how scams work—and how the $1B HealthSplash case exposed a massive ...

Learn who qualifies for Medicare’s GLP-1 Bridge, when $50 Wegovy and Zepbound access begins, and key rules beneficiaries need ...